Analytical Data
-
Gene name
ANOS1
- Application
-
Alternative Names
Kallmann syndrome protein homolog
-
Species
Chicken
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P33005
-
Expression Region
22-281aa
-
Molecular Weight
33.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ANOS1, also known as KAL1, is a gene located on the X chromosome that plays a crucial role in the development of the olfactory system and the formation of reproductive organs. Mutations or deletions in this gene are associated with Kallmann syndrome, a condition characterized by anosmia (loss of the sense of smell) and hypogonadotropic hypogonadism, leading to delayed or absent puberty. The research on ANOS1 recombinant proteins has garnered attention due to its potential implications in understanding the molecular mechanisms underlying Kallmann syndrome and related conditions. By studying these recombinant proteins, researchers aim to elucidate the gene's function in neuronal development and signaling pathways involved in gonadotropin-releasing hormone (GnRH) regulation. The creation of ANOS1 recombinant proteins enables scientists to explore the functional properties of KAL1 in controlled laboratory settings, facilitating the identification of possible therapeutic approaches for treating patients with Kallmann syndrome. This research not only contributes to our knowledge of genetic influences on development and smell but also highlights the broader implications for reproductive health and neurobiology. As our understanding of ANOS1 expands, it may pave the way for innovative treatments and interventions, ultimately improving the quality of life for individuals affected by this genetic disorder.
